Systemic Sclerosis and Malignancy: A Review of Current Data.
Systemic Sclerosis and Malignancy: A Review of Current Data.
复制标题
DOI：
10.14740/jocmr2606w
复制
发表时间：
2016-09
期刊：
影响因子：
--
通讯作者：
Mosak J
中科院分区：
文献类型：
--
作者：
Zeineddine N;Khoury LE;Mosak J
系统性硬化症（SSc）与恶性肿瘤风险增加相关。最常受影响的器官系统是肺、乳房和血液系统。导致SSc患者发生恶性肿瘤的危险因素尚未明确，相关的致病基础尚待解释。SSc患者恶性肿瘤的发生率在不同的报告中是可变的，但最重要的是，关于免疫抑制治疗的作用和自身抗体的影响的问题在大多数现有文献中的答案很弱，有时甚至是矛盾的，医生没有可用的指南来筛选他们的SSc患者的恶性肿瘤。缺乏一个具体定义的高风险的配置文件和恶性肿瘤筛查指南的缺乏SSc患者量身定制的需要更多的研究SSc和癌症的重要性，并应激励风湿病学院制定具体的建议，临床医生遵循，同时接近SSc患者。
Systemic sclerosis (SSc) is associated with increased risk of malignancy. The organ systems most commonly affected are the lungs, the breasts and the hematological system. Risk factors predisposing a SSc patient for development of malignancy are not well defined, and the pathogenic basis of the association is yet to be explained. The incidence of malignancies in SSc patients is variable from one report to another, but most importantly, questions regarding the role of immunosuppressive therapies and the effect of autoantibodies have weak or sometimes contradictory answers in most of the currently available literature and physicians have no available guidelines to screen their SSc patients for malignancies. The lack of a concretely defined high-risk profile and the absence of malignancy screening guidelines tailored for SSc patients raise the importance of the need for more studies on the association of SSc and cancer and should incite rheumatology colleges to develop specific recommendations for the clinician to follow while approaching patients with SSc.